Free PANRE Practice Questions

Endocrinology PANRE practice questions

10 free, board-style Endocrinology questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.

Endocrinology is 8% of the PANRE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1EndocrineMedium
A 58-year-old man presents with decreased libido, fatigue, and morning erections lost over the past year. Two early-morning total testosterone levels are 180 ng/dL and 195 ng/dL (normal 300–1000), with low LH and FSH, consistent with hypogonadism. He has a history of hypertension and a hematocrit of 49%. He asks about starting testosterone replacement therapy and wants to know what to monitor. Which of the following is a recognized risk of testosterone replacement therapy?
  • AOsteoporosis
  • BErythrocytosis
  • CHypocalcemia
  • DAdrenal insufficiency
  • EHyperthyroidism
Reveal answer & full explanation
Correct answer: B — Erythrocytosis
  • AOsteoporosis
  • BErythrocytosis✓
  • CHypocalcemia
  • DAdrenal insufficiency
  • EHyperthyroidism

Why Erythrocytosis is correct

  • Exogenous testosterone stimulates renal erythropoietin production and bone marrow erythropoiesis, leading to dose-dependent increases in hemoglobin and hematocrit
  • Endocrine Society guidelines recommend checking a baseline hematocrit and rechecking at 3–6 months and annually; therapy should be held if hematocrit exceeds 54% because of thromboembolic risk
  • This patient's baseline hematocrit of 49% makes him particularly susceptible; the Endocrine Society lists a baseline hematocrit above 48% (above 50% at high altitude) among conditions in which testosterone carries a high risk of adverse outcomes, so it should be evaluated before therapy is started
  • Other recognized risks include worsening of obstructive sleep apnea, acne, gynecomastia, fluid retention, suppression of spermatogenesis with infertility, and growth of pre-existing prostate cancer

Why the others are wrong

  • Hypocalcemia — not a recognized effect of testosterone; consider PTH, vitamin D, or calcimimetic-related causes instead
  • Adrenal insufficiency — testosterone replacement therapy does not suppress the HPA axis; glucocorticoids do
  • Hyperthyroidism — testosterone replacement therapy does not alter thyroid function in any clinically significant way
  • Osteoporosis — bone loss is a classic effect of androgen deprivation therapy and of untreated hypogonadism, so it is easy to attach to any testosterone-related treatment, but testosterone replacement therapy increases bone mineral density rather than causing osteoporosis.

Additional high-yield points

  • PSA, hematocrit, and symptom assessment are the core testosterone replacement therapy monitoring trio
Question 2EndocrineMedium
A 28-year-old woman reports heat intolerance, palpitations, and a 15-lb weight loss. Examination shows exophthalmos and a diffusely enlarged thyroid. Laboratory studies reveal an undetectable TSH, a markedly elevated free T4, and positive thyroid-stimulating immunoglobulin. Which of the following is the most appropriate initial management?
  • ATotal thyroidectomy
  • BPotassium iodide solution
  • CRadioactive iodine ablation
  • DPropylthiouracil therapy
  • EMethimazole and propranolol
Reveal answer & full explanation
Correct answer: E — Methimazole and propranolol
  • ATotal thyroidectomy
  • BPotassium iodide solution
  • CRadioactive iodine ablation
  • DPropylthiouracil therapy
  • EMethimazole and propranolol✓

Why Methimazole and propranolol is correct

  • Exophthalmos, diffuse goiter, suppressed TSH, high free T4, and positive thyroid-stimulating immunoglobulin establish Graves disease.
  • Initial therapy pairs a thionamide (methimazole), which blocks thyroid hormone synthesis, with a beta-blocker (propranolol) for adrenergic symptom control.
  • Patients are rendered euthyroid before thyroidectomy to avoid precipitating thyroid storm, and methimazole pretreatment before radioactive iodine is advised for those at high risk from transient worsening (older age, cardiovascular disease, severe thyrotoxicosis).

Why the others are wrong

  • Total thyroidectomy — a definitive option, but only after medical stabilization to euthyroid; a right-diagnosis-wrong-step sequencing trap.
  • Potassium iodide solution — iodide (Lugol solution or SSKI) blocks stored hormone release and belongs in thyroid storm or in the roughly 10 days of preoperative preparation after a thionamide has been started; used as initial treatment it gives only transient control before escape and loads the gland with iodine, which blocks radioactive iodine therapy for weeks afterward.
  • Radioactive iodine ablation — a first-line definitive option, but it can worsen active orbitopathy (exophthalmos is present here) and can transiently worsen hyperthyroidism, so starting a thionamide with a beta-blocker is the better initial step; the same sequencing trap.
  • Propylthiouracil therapy — propylthiouracil blocks peripheral conversion of T4 to T3 as well as hormone synthesis, which makes it look like the stronger thionamide, but its risk of severe hepatotoxicity (an FDA boxed warning) limits it to the first trimester of pregnancy, thyroid storm, or a minor adverse reaction to methimazole in a patient who declines radioactive iodine or surgery, none of which is described here; the right-class-wrong-agent trap.
Question 3EndocrineMedium
A 35-year-old female has 6 months of amenorrhea, vaginal dryness, hot flashes, and mood changes. Follicle-stimulating hormone (FSH) is 78 IU/L, luteinizing hormone (LH) is 52 IU/L, and estradiol is 18 pg/mL. Anti-ovarian antibodies are positive. Which of the following is the most likely diagnosis?
  • AAsherman syndrome
  • BHyperprolactinemia
  • CPolycystic ovary syndrome
  • DHypothalamic amenorrhea
  • EPrimary ovarian insufficiency
Reveal answer & full explanation
Correct answer: E — Primary ovarian insufficiency
  • AAsherman syndrome
  • BHyperprolactinemia
  • CPolycystic ovary syndrome
  • DHypothalamic amenorrhea
  • EPrimary ovarian insufficiency✓

Why Primary ovarian insufficiency is correct

  • Primary ovarian insufficiency (POI) is defined as follicle-stimulating hormone (FSH) >25 IU/L on two occasions ≥4 weeks apart before age 40, with menstrual irregularity.
  • High follicle-stimulating hormone (FSH)/luteinizing hormone (LH) plus low estrogen = hypergonadotropic hypogonadism.
  • Distinguish from hypothalamic amenorrhea: low FSH/LH plus low estrogen (hypogonadotropic hypogonadism).
  • Anti-ovarian antibodies suggest an autoimmune etiology.
  • Treatment: hormone replacement therapy (HRT) until average menopausal age (51) to prevent osteoporosis, cardiovascular disease, and cognitive decline.
  • Spontaneous pregnancy remains possible in 5–10% of cases.

Why the others are wrong

  • Asherman syndrome — intrauterine adhesions (usually post-instrumentation) cause amenorrhea with normal FSH/LH and estradiol, and produce no hot flashes or vaginal dryness since estrogen is preserved.
  • Polycystic ovary syndrome — presents with oligomenorrhea plus hyperandrogenism and an elevated LH:FSH ratio with normal or high estradiol, not the high FSH/LH with low estrogen and hypoestrogenic symptoms seen here.
  • Hypothalamic amenorrhea — causes hypogonadotropic hypogonadism with low FSH/LH and low estradiol, the opposite of the markedly elevated gonadotropins in this patient.
  • Hyperprolactinemia — a common, treatable cause of secondary amenorrhea with hypoestrogenic symptoms, but elevated prolactin suppresses GnRH pulsatility and yields low or inappropriately normal FSH/LH, not the markedly elevated gonadotropins seen here; it often causes galactorrhea and is screened for with a serum prolactin level in the amenorrhea workup.
Question 4EndocrineMedium
A 55-year-old man has fatigue, decreased libido, and erectile dysfunction. Morning total testosterone is 185 ng/dL on two occasions, luteinizing hormone (LH) 2.1 mIU/mL, follicle-stimulating hormone (FSH) 1.8 mIU/mL, and prolactin 1,150 ng/mL. MRI of the brain shows a 1.5-cm pituitary mass. Which of the following is the most appropriate first-line treatment?
  • ATestosterone replacement therapy
  • BObservation with serial MRI
  • CCabergoline
  • DExternal beam radiotherapy
  • ETranssphenoidal surgery
Reveal answer & full explanation
Correct answer: C — Cabergoline
  • ATestosterone replacement therapy
  • BObservation with serial MRI
  • CCabergoline✓
  • DExternal beam radiotherapy
  • ETranssphenoidal surgery

Why cabergoline is correct

  • A prolactin of 1,150 ng/mL with a 1.5-cm macroadenoma is diagnostic of a macroprolactinoma; levels >250 ng/mL alongside a macroadenoma confirm a prolactin-secreting tumor rather than stalk-effect hyperprolactinemia from a non-functioning mass.
  • The elevated prolactin suppresses gonadotropin-releasing hormone (GnRH), lowering LH/FSH and testosterone, which explains the hypogonadotropic hypogonadism (low testosterone with low-normal LH and FSH).
  • A dopamine agonist is first-line even for macroprolactinomas; cabergoline is preferred over bromocriptine for greater efficacy and tolerability and shrinks the tumor in most patients (per current Endocrine Society guidance).
  • Testosterone typically normalizes as prolactin falls, so the hypogonadism usually needs no separate treatment initially.

Why the others are wrong

  • Testosterone replacement therapy — Treats the symptom but not the prolactin-secreting tumor and will not shrink the mass; right-target-wrong-mechanism trap of replacing the deficient hormone instead of treating its cause.
  • Transsphenoidal surgery — Reserved for dopamine-agonist resistance or intolerance, or for visual compromise unresponsive to medical therapy; selecting it first is the right-diagnosis-wrong-step trap (it would fit only a non-functioning adenoma, which the markedly elevated prolactin excludes).
  • External beam radiotherapy — Used only for aggressive or refractory tumors after medical and surgical options fail; premature here.
  • Observation with serial MRI — surveillance imaging suits an incidentally found nonfunctioning pituitary adenoma without mass effect, but a prolactin of 1,150 ng/mL with a macroadenoma and symptomatic hypogonadism marks a functioning tumor that needs treatment, and a dopamine agonist usually restores gonadal function and shrinks the mass; under-treatment trap of managing a prolactinoma like an incidentaloma.

Additional high-yield points

  • Document visual fields in any macroadenoma, and monitor response with serial prolactin levels and repeat MRI.
Question 5EndocrineMedium
A 45-year-old female has hypertension, spontaneous hypokalemia (K+ 2.8), and metabolic alkalosis. Plasma aldosterone is 38 ng/dL with suppressed renin (aldosterone-to-renin ratio (ARR) 58). 24-hour urinary aldosterone remains elevated after salt loading. CT adrenals is normal. Which of the following is the most appropriate next step in management?
  • AMRI adrenals
  • BLaparoscopic adrenalectomy
  • CEmpiric spironolactone
  • DCaptopril challenge test
  • EAdrenal venous sampling
Reveal answer & full explanation
Correct answer: E — Adrenal venous sampling
  • AMRI adrenals
  • BLaparoscopic adrenalectomy
  • CEmpiric spironolactone
  • DCaptopril challenge test
  • EAdrenal venous sampling✓

Why Adrenal venous sampling is correct

  • Primary hyperaldosteronism has been confirmed biochemically (aldosterone suppression test positive with elevated 24-hour urinary aldosterone after salt loading)
  • CT adrenals being normal does NOT exclude unilateral adenoma — CT misses 20–40% of adenomas under 1 cm
  • Adrenal venous sampling (AVS) is the gold standard to lateralize disease before surgery
  • Lateralization index over 4:1 = unilateral disease → laparoscopic adrenalectomy, which is curative in 50% and improves blood pressure in 90%
  • Lateralization index under 3:1 = bilateral hyperplasia → lifetime spironolactone or eplerenone
  • AVS should be performed at centers with expertise

Why the others are wrong

  • Laparoscopic adrenalectomy — surgery is offered only after sampling proves unilateral aldosterone excess; with a normal CT and no lateralization, operating risks removing a normal gland and leaving bilateral hyperplasia untreated
  • Empiric spironolactone — appropriate for bilateral hyperplasia, but lateralization must first be established to determine whether surgery is indicated
  • MRI adrenals — MRI is not superior to CT for adrenal adenoma detection and is not the standard next step once CT is negative and biochemical confirmation is complete; AVS is indicated
  • Captopril challenge test — captopril challenge is a recognized confirmatory test for primary aldosteronism, but confirmation is already complete here (urinary aldosterone remained elevated after salt loading), so another confirmatory test adds nothing; the open question is lateralization, which AVS answers when CT is normal
Question 6EndocrineMedium
A 30-year-old female has a 3cm thyroid mass, hoarseness, ipsilateral cervical lymphadenopathy, a family history of multiple endocrine neoplasia type 2A (MEN2A), and a calcitonin of 4,800 pg/mL. Genetic testing confirms a RET proto-oncogene mutation. Which of the following is the most likely diagnosis?
  • AHürthle cell thyroid carcinoma
  • BFollicular thyroid carcinoma
  • CAnaplastic thyroid carcinoma
  • DMedullary thyroid carcinoma
  • EPapillary thyroid carcinoma
Reveal answer & full explanation
Correct answer: D — Medullary thyroid carcinoma
  • AHürthle cell thyroid carcinoma
  • BFollicular thyroid carcinoma
  • CAnaplastic thyroid carcinoma
  • DMedullary thyroid carcinoma✓
  • EPapillary thyroid carcinoma

Why Medullary thyroid carcinoma is correct

  • RET proto-oncogene mutation confirms a hereditary syndrome; markedly elevated calcitonin (4,800 pg/mL) is the tumor marker for medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia type 2A (MEN2A) = medullary thyroid carcinoma + pheochromocytoma (40%) + primary hyperparathyroidism (20–30%)
  • RET proto-oncogene mutations drive MTC in both sporadic and hereditary forms

Why the others are wrong

  • Hürthle cell thyroid carcinoma — an oncocytic carcinoma derived from follicular epithelium; it does not arise from parafollicular C cells, does not raise calcitonin, and carries no germline RET point mutation or MEN2A association
  • Follicular thyroid carcinoma — derived from follicular cells, not parafollicular C-cells; does not produce calcitonin; not linked to RET/MEN2A
  • Papillary thyroid carcinoma — most common thyroid cancer; can have RET/PTC rearrangements but not RET point mutations; does not secrete calcitonin
  • Anaplastic thyroid carcinoma — hoarseness with a neck mass and nodal spread suggests an aggressive invasive cancer, but anaplastic carcinoma is a dedifferentiated tumor of follicular epithelium that typically presents as a rapidly enlarging mass in older adults; it does not secrete calcitonin and has no germline RET or MEN2A association

Additional high-yield points

  • Critical pre-operative step: rule out pheochromocytoma BEFORE thyroid surgery — undiagnosed pheo during surgery can cause hypertensive crisis
  • Order plasma or urine metanephrines first; if pheo present: adrenalectomy first, THEN thyroidectomy
  • Surgical treatment: total thyroidectomy plus central neck dissection for MTC
  • Prophylactic thyroidectomy offered to RET mutation carriers based on codon-specific risk stratification
  • Calcitonin serves as the tumor marker for MTC diagnosis and recurrence monitoring
Question 7EndocrineMedium
A 29-year-old woman with type 1 diabetes presents with nausea, vomiting, and abdominal pain. She ran out of insulin 2 days ago. Labs: glucose 520 mg/dL, pH 7.18, bicarbonate 10 mEq/L, anion gap 24, ketones positive in blood and urine. What is the most important initial treatment?
  • AIV potassium chloride infusion
  • BSodium bicarbonate infusion
  • CIntravenous half-normal saline bolus
  • DIV insulin bolus
  • EIV normal saline fluid resuscitation
Reveal answer & full explanation
Correct answer: E — IV normal saline fluid resuscitation
  • AIV potassium chloride infusion
  • BSodium bicarbonate infusion
  • CIntravenous half-normal saline bolus
  • DIV insulin bolus
  • EIV normal saline fluid resuscitation✓

Why IV normal saline fluid resuscitation is correct

  • In diabetic ketoacidosis (DKA) management, the first step is aggressive IV fluid resuscitation with isotonic saline (500-1,000 mL per hour for the first 2-4 hours in adults without cardiac or kidney compromise) to restore intravascular volume.
  • Insulin is started after fluids and only after potassium is 3.5 mEq/L or higher, because insulin drives K+ intracellularly and hypokalemia must be corrected first.

Why the others are wrong

  • Intravenous half-normal saline bolus — hypotonic fluid is the wrong choice for initial volume expansion; 0.9% saline is given first to refill the intravascular space, and 0.45% saline belongs to the later replacement phase once perfusion is restored and the corrected sodium is normal or high.
  • IV insulin bolus — An insulin bolus without fluids can worsen hemodynamics; fluids must be initiated first.
  • Sodium bicarbonate infusion — Bicarbonate is not routinely given in DKA; it is considered only for severe acidosis with pH below 7.0 (2024 ADA/EASD consensus), and this patient's pH is 7.18.
  • IV potassium chloride infusion — potassium is a real priority, since total-body K+ is depleted and insulin will drive it into cells, but the serum level is often normal or even high at presentation and has not been reported here; potassium is added to the fluids once the level and urine output are known, so restoring intravascular volume with isotonic saline still comes first.
Question 8EndocrineMedium
A 40-year-old male has hypertension since age 30, episodes of severe headache, palpitations, and diaphoresis, and is now found to have a right adrenal mass on CT. Plasma free metanephrines are markedly elevated. He is started on phenoxybenzamine preoperatively. His father had similar episodes. He also has a history of medullary thyroid carcinoma treated 3 years ago. Which of the following is the most likely underlying syndrome?
  • ANeurofibromatosis type 1
  • BVon Hippel-Lindau syndrome
  • CMEN2A
  • DMEN1
  • EFamilial paraganglioma
Reveal answer & full explanation
Correct answer: C — MEN2A
  • ANeurofibromatosis type 1
  • BVon Hippel-Lindau syndrome
  • CMEN2A✓
  • DMEN1
  • EFamilial paraganglioma

Why MEN2A is correct

  • MEN2A (multiple endocrine neoplasia type 2A) is caused by RET proto-oncogene mutations (most commonly codon 634)
  • Components: (1) medullary thyroid carcinoma (MTC): 95% penetrance, often first manifestation; (2) pheochromocytoma: 50% penetrance, bilateral in 50%, rarely malignant; (3) primary hyperparathyroidism: 20-30% penetrance
  • This patient has pheochromocytoma (elevated plasma free metanephrines, adrenal mass) plus a history of medullary thyroid carcinoma — two of the three MEN2A components
  • Autosomal dominant inheritance; the family history of similar episodes supports a hereditary syndrome

Why the others are wrong

  • Neurofibromatosis type 1 — associated with pheochromocytoma and neurofibromas but not MTC, and no RET mutation (right-concept-wrong-syndrome)
  • MEN1 — components are parathyroid adenoma, pituitary adenoma, and pancreatic neuroendocrine tumor, without MTC or pheochromocytoma (confused-with MEN2)
  • Von Hippel-Lindau syndrome — associated with pheochromocytoma, clear cell renal cell carcinoma, and hemangioblastomas, but not MTC (anchoring on pheochromocytoma)
  • Familial paraganglioma — germline succinate dehydrogenase (SDHx) mutations cause hereditary pheochromocytoma and paraganglioma with autosomal dominant inheritance, but these tumors are often extra-adrenal and the syndrome does not include medullary thyroid carcinoma or a RET mutation (confused-with hereditary pheochromocytoma)

Additional high-yield points

  • Genetic testing: all first-degree relatives should have RET mutation testing
  • Prophylactic thyroidectomy timing is codon-specific: codon 918 (MEN2B) = highest risk — thyroidectomy within the first year of life (ATA 2015)
  • Management order: rule out pheochromocytoma BEFORE thyroid surgery to avoid anesthesia-triggered hypertensive crisis
  • Calcitonin is the tumor marker for MTC surveillance
  • MEN2B: RET codon 918, MTC plus pheochromocytoma plus marfanoid habitus plus mucosal neuromas — NO hyperparathyroidism
Question 9EndocrineMedium
A 35-year-old female has episodic headaches, flushing, palpitations, watery diarrhea, and markedly elevated 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) (68 mg/day). CT shows an ileal mass with multiple liver metastases. Ga-68-DOTATATE PET-CT confirms somatostatin-receptor-positive uptake at multiple sites. Which of the following is the most appropriate first-line systemic therapy?
  • AInterferon alfa-2b
  • BTelotristat ethyl
  • CHistamine-1 and histamine-2 receptor blockers
  • DStreptozocin-based chemotherapy
  • EOctreotide LAR
Reveal answer & full explanation
Correct answer: E — Octreotide LAR
  • AInterferon alfa-2b
  • BTelotristat ethyl
  • CHistamine-1 and histamine-2 receptor blockers
  • DStreptozocin-based chemotherapy
  • EOctreotide LAR✓

Why Octreotide LAR is correct

  • Carcinoid syndrome occurs when liver metastases secrete serotonin into systemic circulation, bypassing hepatic first-pass metabolism
  • Classic triad: flushing, diarrhea, bronchospasm; right-sided cardiac valvular disease develops in chronic cases
  • Biomarkers: 24h urine 5-hydroxyindoleacetic acid (5-HIAA) or chromogranin A
  • Somatostatin analogues (octreotide long-acting release (LAR) 20-30mg monthly; lanreotide 120mg SQ monthly) relieve symptoms and have antiproliferative effects
  • PROMID trial: octreotide LAR doubled time-to-tumor-progression; CLARINET trial: lanreotide improved progression-free survival (PFS)

Why the others are wrong

  • Streptozocin-based chemotherapy — cytotoxic chemotherapy is reserved for pancreatic neuroendocrine tumors or high-grade disease; response rates in well-differentiated midgut carcinoid are low, so it is not the first systemic therapy offered (right-modality-wrong-tumor)
  • Histamine-1 and histamine-2 receptor blockers — used for flushing in systemic mastocytosis, not for serotonin-mediated carcinoid syndrome (confused-with mastocytosis)
  • Interferon alfa-2b — a second-line option added after somatostatin analogue failure; flu-like illness, cytopenias, and depression keep it out of first-line use (right-concept-wrong-sequence)
  • Telotristat ethyl — telotristat inhibits tryptophan hydroxylase to reduce serotonin production and is approved specifically for carcinoid syndrome diarrhea, but only as an add-on when diarrhea remains inadequately controlled on a somatostatin analogue; it has no proven antiproliferative effect and does not replace octreotide LAR as first-line therapy (right-drug-wrong-sequence)

Additional high-yield points

  • Preferred localization: Ga-68-DOTATATE PET-CT (superior to octreotide scintigraphy)
  • Lu-177-DOTATATE (peptide receptor radionuclide therapy (PRRT), Lutathera): NETTER-1 trial significantly improved PFS in progressive somatostatin receptor-positive mid-gut neuroendocrine tumors (NETs)
  • Everolimus plus octreotide is another treatment option (RADIANT-3 trial)
  • Carcinoid crisis prevention: IV octreotide infusion during any invasive procedures
Question 10EndocrineMedium
A 45-year-old man has an incidentally discovered 2.2 cm adrenal mass on CT showing a homogeneous, well-marginated lesion with a noncontrast attenuation of 8 Hounsfield units, consistent with a lipid-rich adenoma. He is normotensive, normokalemic, and has no symptoms of hormone excess. Which of the following is the most appropriate next step in evaluation?
  • APlasma free metanephrines measurement
  • BCT-guided percutaneous adrenal biopsy
  • CRepeat noncontrast adrenal CT in 12 months
  • D24-hour urinary free cortisol measurement
  • EOvernight dexamethasone suppression test
Reveal answer & full explanation
Correct answer: E — Overnight dexamethasone suppression test
  • APlasma free metanephrines measurement
  • BCT-guided percutaneous adrenal biopsy
  • CRepeat noncontrast adrenal CT in 12 months
  • D24-hour urinary free cortisol measurement
  • EOvernight dexamethasone suppression test✓

Why Overnight dexamethasone suppression test is correct

  • Every adrenal incidentaloma requires biochemical screening for autonomous cortisol secretion; the 1-mg overnight dexamethasone suppression test (DST) is the mandated first test in all patients regardless of size or imaging
  • A morning cortisol >1.8 ug/dL after 1 mg dexamethasone defines possible mild autonomous cortisol secretion (MACS), the most common functional abnormality in incidentalomas
  • The 2023 ESE/ENSAT guideline classifies a homogeneous lesion with noncontrast attenuation <=10 HU as radiographically benign (lipid-rich adenoma), so the DST is the essential next step here
  • Aldosterone-to-renin ratio is added only with hypertension or hypokalemia, neither of which this patient has

Why the others are wrong

  • Plasma free metanephrines measurement — current ESE guidance does not require routine pheochromocytoma screening for a clearly lipid-rich lesion <=10 HU, since such density effectively excludes pheochromocytoma; older AACE/AAES guidance screened every incidentaloma and many US clinicians still add it, but at this density it is optional, whereas the DST is the one test every guideline requires (confused-with non-lipid-rich lesions)
  • CT-guided percutaneous adrenal biopsy — biopsy cannot reliably distinguish adenoma from adrenocortical carcinoma, carries seeding/bleeding risk, and is never the first step before excluding pheochromocytoma and cortisol excess (premature closure)
  • Repeat noncontrast adrenal CT in 12 months — imaging surveillance does not address the mandatory biochemical screening that must occur at discovery (anchoring)
  • 24-hour urinary free cortisol measurement — tempting because it is a familiar screening test for Cushing syndrome, but the mild autonomous cortisol secretion seen in incidentalomas usually leaves 24-hour urinary cortisol within normal limits, so the test is too insensitive to exclude MACS and the ESE/ENSAT guideline does not use it as the screen here (right-concept-wrong-test)

Additional high-yield points

  • Surgery is reserved for masses >4 cm, indeterminate/malignant imaging features, or confirmed clinically significant hormone excess

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANRE question →

Endocrinology PANRE practice: FAQ

Are these Endocrinology PANRE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANRE is Endocrinology?

Endocrinology makes up 8% of the PANRE content blueprint. FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Endocrinology questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Endocrinology questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.